| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 8.46 Billion | USD 17.94 Billion | 8.70% | 2024 |
FrequentlyAsked Questions
Point-of-care molecular diagnostics is a type of medical testing that allows doctors to detect diseases at or near the patient’s location using genetic material, such as DNA or RNA. Instead of sending samples to a distant laboratory and waiting for results, these tests are performed on-site, providing quick results.
According to a study, the global point-of-care molecular diagnostics market size was worth around USD 8.46 billion in 2024 and is predicted to grow to around USD 17.94 billion by 2034.
The CAGR value of the point-of-care molecular diagnostics market is expected to be around 8.70% during 2025–2034.
North America is expected to lead the global point-of-care molecular diagnostics market during the forecast period, driven by advanced healthcare infrastructure, high diagnostic testing volumes, strong reimbursement frameworks, and the presence of leading global diagnostics companies.
The major players in the global point-of-care molecular diagnostics market include Abbott Laboratories, Roche Diagnostics, bioMerieux, Danaher Corporation, Becton Dickinson and Company, Hologic Incorporated, Qiagen, Meridian Bioscience, Cepheid, and Chembio Diagnostics.
The report examines key aspects of the point-of-care molecular diagnostics market, including a thorough analysis of current growth drivers and restraints, emerging opportunities, significant challenges facing manufacturers and healthcare providers, competitive landscape analysis, detailed regional market breakdowns, and a forward-looking outlook across all major product types, technologies, applications, and geographies.
The point-of-care molecular diagnostics market is expected to see steady growth led by North America, supported by strong healthcare infrastructure and high adoption of advanced diagnostics. Europe follows as the second-largest region, with consistent growth driven by quality standards and the expanding use of rapid testing.
The point-of-care molecular diagnostics market offers opportunities to develop affordable devices, AI-based diagnostic platforms, and home-testing kits. Partnerships among healthcare providers, technology firms, and diagnostic companies can accelerate innovation, expand access, and strengthen global distribution networks.
The point-of-care molecular diagnostics market is shifting toward faster, portable, and easy-to-use tests, with growing preference for home-based testing and digital connectivity for quick results and remote care.
HappyClients